Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Aug;85(4):509–517. doi: 10.1054/bjoc.2001.1953

Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients

M A Bensmaïne 1, M Marty 2, A de Gramont 3, S Brienza 4, F Lévi 5, M Ducreux 6, E François 7, E Gamelin 8, H Bleiberg 9, E Cvitkovic 1,5
PMCID: PMC2364084  PMID: 11506488

Abstract

A statistical analysis was performed on the patient data collected from two compassionate-use programmes using oxaliplatin (Eloxatin®) + 5-fluorouracil (5-FU) ± folinic acid (FA), to identify predictive factors for oxaliplatin-based salvage treatment in patients with 5-FU-resistant advanced colorectal cancer (ACRC). 481 5-FU-resistant ACRC patients, most with performance status ≤ 2, ≥ 3 involved sites, and ≥ 2 prior lines of chemotherapy, received oxaliplatin + 5-FU ± FA. Prognostic factors associated with overall response rate (ORR), time to progression (TTP) and overall survival (OS) were identified using univariate and multivariate logistic and/or Cox proportional hazards analyses. The ORR was 16% (95% CI: 13–20), the median TTP was 4.2 months (95% CI: 3.4–4.6), and the median OS was 9.6 months (95% CI: 8.6–10.6). The multivariate analysis indicated poor (≥ 2 WHO) performance status (PS), a large number of prior chemotherapy regimens (≥ 3), a low baseline haemoglobin level (< 10 g/dl), and a triweekly (vs biweekly) treatment administration schedule as significantly associated (P< 0.05) with a lower ORR. Sex (male), number of organs involved (≥3) and alkaline phosphatase (AP) level (≥ 2 × the upper limit of normal) were associated (P< 0.05) with shorter TTP. Poor PS, a large number of organs involved, and elevated AP were independently and significantly correlated with shorter OS. Our analysis identified a relationship between efficacy results of oxaliplatin + 5-FU ± FA treatment in 5-FU-resistant ACRC patients and baseline prognostic factors related to PS, extent of disease and number of prior regimens. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: clinical resistance, multivariate analysis, salvage chemotherapy

Full Text

The Full Text of this article is available as a PDF (85.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. André T., Bensmaine M. A., Louvet C., François E., Lucas V., Desseigne F., Beerblock K., Bouché O., Carola E., Merrouche Y. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol. 1999 Nov;17(11):3560–3568. doi: 10.1200/JCO.1999.17.11.3560. [DOI] [PubMed] [Google Scholar]
  2. Bertheault-Cvitkovic F., Jami A., Ithzaki M., Brummer P. D., Brienza S., Adam R., Kunstlinger F., Bismuth H., Misset J. L., Lévi F. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol. 1996 Nov;14(11):2950–2958. doi: 10.1200/JCO.1996.14.11.2950. [DOI] [PubMed] [Google Scholar]
  3. Boring C. C., Squires T. S., Tong T. Cancer statistics, 1992. CA Cancer J Clin. 1992 Jan-Feb;42(1):19–38. doi: 10.3322/canjclin.42.1.19. [DOI] [PubMed] [Google Scholar]
  4. Bécouarn Y., Ychou M., Ducreux M., Borel C., Bertheault-Cvitkovic F., Seitz J. F., Nasca S., Nguyen T. D., Paillot B., Raoul J. L. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol. 1998 Aug;16(8):2739–2744. doi: 10.1200/JCO.1998.16.8.2739. [DOI] [PubMed] [Google Scholar]
  5. Douillard J. Y., Cunningham D., Roth A. D., Navarro M., James R. D., Karasek P., Jandik P., Iveson T., Carmichael J., Alakl M. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000 Mar 25;355(9209):1041–1047. doi: 10.1016/s0140-6736(00)02034-1. [DOI] [PubMed] [Google Scholar]
  6. Falcone A., Cianci C., Pfanner E., Bertuccelli M., Brunetti I., Muttini M. P., Dargenio F., Ricci S., Conte P. F. Continuous-infusion 5-fluorouracil in metastatic colorectal cancer patients pretreated with bolus 5-fluorouracil: clinical evidence of incomplete cross-resistance. Ann Oncol. 1994 Mar;5(3):291–291. doi: 10.1093/oxfordjournals.annonc.a058813. [DOI] [PubMed] [Google Scholar]
  7. Gerard B., Bleiberg H., Van Daele D., Gil T., Hendlisz A., Di Leo A., Fernez B., Brienza S. Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer. Anticancer Drugs. 1998 Apr;9(4):301–305. doi: 10.1097/00001813-199804000-00002. [DOI] [PubMed] [Google Scholar]
  8. Giacchetti S., Perpoint B., Zidani R., Le Bail N., Faggiuolo R., Focan C., Chollet P., Llory J. F., Letourneau Y., Coudert B. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000 Jan;18(1):136–147. doi: 10.1200/JCO.2000.18.1.136. [DOI] [PubMed] [Google Scholar]
  9. Goldwasser F., Gross-Goupil M., Tigaud J. M., Di Palma M., Marceau-Suissa J., Wasserman E., Yovine A., Misset J. L., Cvitkovic E. Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients. Ann Oncol. 2000 Nov;11(11):1463–1470. doi: 10.1023/a:1026535824044. [DOI] [PubMed] [Google Scholar]
  10. Graf W., Påhlman L., Bergström R., Glimelius B. The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. Br J Cancer. 1994 Sep;70(3):559–563. doi: 10.1038/bjc.1994.345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hill M., Norman A., Cunningham D., Findlay M., Nicolson V., Hill A., Iveson A., Evans C., Joffe J., Nicolson M. Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol. 1995 Jun;13(6):1297–1302. doi: 10.1200/JCO.1995.13.6.1297. [DOI] [PubMed] [Google Scholar]
  12. Levi F., Perpoint B., Garufi C., Focan C., Chollet P., Depres-Brummer P., Zidani R., Brienza S., Itzhaki M., Iacobelli S. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer. 1993;29A(9):1280–1284. doi: 10.1016/0959-8049(93)90073-o. [DOI] [PubMed] [Google Scholar]
  13. LoRusso P., Pazdur R., Redman B. G., Kinzie J., Vaitkevicius V. Low-dose continuous infusion 5-fluorouracil and cisplatin: phase II evaluation in advanced colorectal carcinoma. Am J Clin Oncol. 1989 Dec;12(6):486–490. doi: 10.1097/00000421-198912000-00005. [DOI] [PubMed] [Google Scholar]
  14. Lévi F., Misset J. L., Brienza S., Adam R., Metzger G., Itzakhi M., Caussanel J. P., Kunstlinger F., Lecouturier S., Descorps-Declère A. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer. 1992 Feb 15;69(4):893–900. doi: 10.1002/1097-0142(19920215)69:4<893::aid-cncr2820690410>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  15. Machover D., Diaz-Rubio E., de Gramont A., Schilf A., Gastiaburu J. J., Brienza S., Itzhaki M., Metzger G., N'Daw D., Vignoud J. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol. 1996 Jan;7(1):95–98. doi: 10.1093/oxfordjournals.annonc.a010489. [DOI] [PubMed] [Google Scholar]
  16. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  17. Petrelli N. J., Madejewicz S., Rustum Y., Herrera L., Creaven P. J., Plager J., Soloman J., Mittelman A. Combination chemotherapy of cisplatin and 5-fluorouracil for advanced colorectal adenocarcinoma. Cancer Chemother Pharmacol. 1989;23(1):57–60. doi: 10.1007/BF00258460. [DOI] [PubMed] [Google Scholar]
  18. Raymond E., Chaney S. G., Taamma A., Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998 Oct;9(10):1053–1071. doi: 10.1023/a:1008213732429. [DOI] [PubMed] [Google Scholar]
  19. Raymond E., Faivre S., Woynarowski J. M., Chaney S. G. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol. 1998 Apr;25(2 Suppl 5):4–12. [PubMed] [Google Scholar]
  20. Rougier P., Van Cutsem E., Bajetta E., Niederle N., Possinger K., Labianca R., Navarro M., Morant R., Bleiberg H., Wils J. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998 Oct 31;352(9138):1407–1412. doi: 10.1016/S0140-6736(98)03085-2. [DOI] [PubMed] [Google Scholar]
  21. Saltz L. B., Cox J. V., Blanke C., Rosen L. S., Fehrenbacher L., Moore M. J., Maroun J. A., Ackland S. P., Locker P. K., Pirotta N. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000 Sep 28;343(13):905–914. doi: 10.1056/NEJM200009283431302. [DOI] [PubMed] [Google Scholar]
  22. Warr D., McKinney S., Tannock I. Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response. J Clin Oncol. 1984 Sep;2(9):1040–1046. doi: 10.1200/JCO.1984.2.9.1040. [DOI] [PubMed] [Google Scholar]
  23. Wasserman E., Cuvier C., Lokiec F., Goldwasser F., Kalla S., Méry-Mignard D., Ouldkaci M., Besmaine A., Dupont-André G., Mahjoubi M. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. J Clin Oncol. 1999 Jun;17(6):1751–1759. doi: 10.1200/JCO.1999.17.6.1751. [DOI] [PubMed] [Google Scholar]
  24. Whitehead R. P., Fleming T. R., Macdonald J. S., Ahmann F. R., Garewal H. S., Kuebler J. P. A phase II study of chemotherapy of metastatic colorectal carcinoma with 5-fluorouracil plus cisplatin. A Southwest Oncology Group study. Invest New Drugs. 1991 Nov;9(4):345–347. doi: 10.1007/BF00183578. [DOI] [PubMed] [Google Scholar]
  25. de Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., Boni C., Cortes-Funes H., Cervantes A., Freyer G. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000 Aug;18(16):2938–2947. doi: 10.1200/JCO.2000.18.16.2938. [DOI] [PubMed] [Google Scholar]
  26. de Gramont A., Vignoud J., Tournigand C., Louvet C., André T., Varette C., Raymond E., Moreau S., Le Bail N., Krulik M. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer. 1997 Feb;33(2):214–219. doi: 10.1016/s0959-8049(96)00370-x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES